BOSTON SCIENTIFIC CORP (BSX.DE) Stock Price & Overview
FRA:BSX • US1011371077
The current stock price of BSX.DE is 62 EUR. Today BSX.DE is down by -1.9%. In the past month the price decreased by -5.49%. In the past year, price decreased by -31.49%.
BSX.DE Key Statistics
- Market Cap
- 91.947B
- P/E
- 23.57
- Fwd P/E
- 20.57
- EPS (TTM)
- 2.63
- Dividend Yield
- N/A
BSX.DE Stock Performance
BSX.DE Stock Chart
BSX.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BSX.DE. When comparing the yearly performance of all stocks, BSX.DE is a bad performer in the overall market: 93.63% of all stocks are doing better.
BSX.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE. BSX.DE has an excellent profitability rating, but there are some minor concerns on its financial health.
BSX.DE Earnings
On February 4, 2026 BSX.DE reported an EPS of 0.8 and a revenue of 5.29B. The company beat EPS expectations (1.62% surprise) and missed revenue expectations (-0.88% surprise).
BSX.DE Forecast & Estimates
40 analysts have analysed BSX.DE and the average price target is 91.04 EUR. This implies a price increase of 46.84% is expected in the next year compared to the current price of 62.
For the next year, analysts expect an EPS growth of 14.83% and a revenue growth 10.95% for BSX.DE
BSX.DE Groups
Sector & Classification
BSX.DE Financial Highlights
Over the last trailing twelve months BSX.DE reported a non-GAAP Earnings per Share(EPS) of 2.63. The EPS increased by 21.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.42% | ||
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| Debt/Equity | 0.48 |
BSX.DE Ownership
BSX.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 14.75 | 103.215B | ||
| SHL | SIEMENS HEALTHINEERS AG | 15.11 | 45.684B | ||
| 1PHIA | KONINKLIJKE PHILIPS NV | 17.51 | 25.662B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 16.36 | 24.632B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 16.42 | 24.555B | ||
| BIM | BIOMERIEUX | 19.06 | 11.274B | ||
| DIA | DIASORIN SPA | 16.86 | 3.845B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 18.63 | 3.66B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 10.61 | 2.27B | ||
| DRW3 | DRAEGERWERK AG - PREF | 11.95 | 1.653B | ||
| DRW8 | DRAEGERWERK AG | 9.87 | 1.343B | ||
| ELN | EL.EN. SPA | 21.21 | 1.065B | ||
| EUZ | ECKERT & ZIEGLER SE | 18.11 | 952.165M |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About BSX.DE
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS US
Employees: 53000
Phone: 13026365400
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What does BOSTON SCIENTIFIC CORP do?
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
What is the current price of BSX stock?
The current stock price of BSX.DE is 62 EUR. The price decreased by -1.9% in the last trading session.
Does BOSTON SCIENTIFIC CORP pay dividends?
BSX.DE does not pay a dividend.
What is the ChartMill rating of BOSTON SCIENTIFIC CORP stock?
BSX.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the employee count for BSX stock?
BOSTON SCIENTIFIC CORP (BSX.DE) currently has 53000 employees.